TY - JOUR
T1 - Acute and Chronic Demyelinating Neuropathies after COVID-19 Vaccination
T2 - A Report of 4 Cases
AU - Dennis, Erin
AU - Hartman, Elizabeth
AU - Cortes-Penfield, Nicolas
AU - Piccione, Ezequiel
AU - Thaisetthawatkul, Pariwat
N1 - Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023/3/1
Y1 - 2023/3/1
N2 - Objectives:To report demyelinating neuropathies after COVID-19 vaccination.Methods:Case report.Results:Four cases of demyelinating neuropathies after COVID-19 vaccination were identified at the University of Nebraska Medical Center from May to September 2021. Three were male and 1 was a female, ages 26-64 years. Three cases received Pfizer-BioNTech vaccine and 1 Johnson & Johnson. Symptom onset ranged from 2 to 21 days after vaccination. Two cases had progressive limb weakness, 3 had facial diplegia, and all had sensory symptoms and areflexia. The diagnosis was acute inflammatory demyelinating polyneuropathy in 1 case and chronic inflammatory demyelinating polyradiculoneuropathy in 3. All cases received treatment with intravenous immunoglobulin, with significant improvement in 3 of 4 who had a long-Term outpatient follow-up.Conclusions:Continued identification and reporting of cases of demyelinating neuropathies after COVID-19 vaccination is essential to determine whether a causative association is present.
AB - Objectives:To report demyelinating neuropathies after COVID-19 vaccination.Methods:Case report.Results:Four cases of demyelinating neuropathies after COVID-19 vaccination were identified at the University of Nebraska Medical Center from May to September 2021. Three were male and 1 was a female, ages 26-64 years. Three cases received Pfizer-BioNTech vaccine and 1 Johnson & Johnson. Symptom onset ranged from 2 to 21 days after vaccination. Two cases had progressive limb weakness, 3 had facial diplegia, and all had sensory symptoms and areflexia. The diagnosis was acute inflammatory demyelinating polyneuropathy in 1 case and chronic inflammatory demyelinating polyradiculoneuropathy in 3. All cases received treatment with intravenous immunoglobulin, with significant improvement in 3 of 4 who had a long-Term outpatient follow-up.Conclusions:Continued identification and reporting of cases of demyelinating neuropathies after COVID-19 vaccination is essential to determine whether a causative association is present.
KW - COVID-19 vaccination
KW - acute demyelinating polyneuropathy
KW - chronic inflammatory demyelinating polyradiculoneuropathy
KW - facial diplegia
UR - http://www.scopus.com/inward/record.url?scp=85148678974&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148678974&partnerID=8YFLogxK
U2 - 10.1097/CND.0000000000000418
DO - 10.1097/CND.0000000000000418
M3 - Article
C2 - 36809202
AN - SCOPUS:85148678974
SN - 1522-0443
VL - 24
SP - 147
EP - 156
JO - Journal of Clinical Neuromuscular Disease
JF - Journal of Clinical Neuromuscular Disease
IS - 3
ER -